🔬Biotech Firm Launches $350M Fund to Build Companies From Scratch
A new fund is betting big on biotech startups from scratch
TL;DR
A venture firm launched a $350 million fund to build biotech companies from the ground up. One-third of funds go into in-house projects, with AI playing a key role in drug discovery.
A new venture capital firm has launched a $350 million fund dedicated to building biotech startups from scratch. This isn't just about investing in existing ideas; it's about creating companies and technologies that don't yet exist. The firm is pioneering epigenetic gene editing, aiming for safer delivery methods to specific cells. Why does this matter? Because the pharma industry is facing a massive patent cliff, with record cash reserves from pandemic profits. Pharma giants like Eli Lilly are already making huge exits in antibody drug conjugates, buying up innovative startups left and right. The NIH budget has stagnated, but AI is stepping in to accelerate drug discovery at unprecedented speeds.
Key Points
The new fund has $350 million dedicated to building and funding biotech startups from scratch
One-third ($117M) goes into internal projects spun up by the firm itself, pioneering epigenetic gene editing tech
Two companies in the first fund came directly out of a grant, with no strings attached
The NIH budget has not grown for about a decade and is shrinking relative to inflation
AI is being used to create synthetic control arms for clinical trials, halving patient numbers needed
Why It Matters
If you're in the biotech or pharma industry, this fund could be your next big opportunity. With record cash reserves from pandemic profits and a massive patent cliff looming, pharma giants are looking to buy up innovative startups. The NIH budget is shrinking, but AI is stepping in to accelerate drug discovery at unprecedented speeds.
Frequently Asked Questions
Why does this matter?
If you're in the biotech or pharma industry, this fund could be your next big opportunity. With record cash reserves from pandemic profits and a massive patent cliff looming, pharma giants are looking to buy up innovative startups. The NIH budget is shrinking, but AI is stepping in to accelerate drug discovery at unprecedented speeds.
What happened?
A venture firm launched a $350 million fund to build biotech companies from the ground up. One-third of funds go into in-house projects, with AI playing a key role in drug discovery.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.